Brokerages Set AstraZeneca PLC (LON:AZN) PT at GBX 7,935.67

Shares of AstraZeneca PLC (LON:AZN) have received an average rating of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is GBX 7,935.67 ($98.73).

A number of analysts have commented on AZN shares. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.74) target price on shares of AstraZeneca in a research report on Monday, January 27th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($174.17) target price on shares of AstraZeneca in a research report on Friday, November 22nd.

AstraZeneca Price Performance

Shares of AZN stock opened at £111.44 ($138.64) on Thursday. The stock has a 50 day moving average of £106.90 and a two-hundred day moving average of £115.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12 month low of GBX 9,461 ($117.70) and a 12 month high of £133.88 ($166.56). The company has a market capitalization of £172.73 billion, a P/E ratio of 3,537.78, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Tony Mok purchased 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of £126.80 ($157.75) per share, with a total value of £190,200 ($236,626.03). Also, insider Pascal Soriot purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($126.93) per share, with a total value of £2,040,600 ($2,538,691.22). Insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.